Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314873 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
A Phase 1 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00314873 is a Phase 1 study that has completed, run by Indiana University. The registered enrollment target is 11 participants.
The verdict
NCT00314873, a Phase 1 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit and/or PDGF. If this current trial is positive, it opens the door to evaluate other combination of drugs with imatinib in thymic tumors.
Interventions
- DRUG Gleevec (imatinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-04 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00314873
The ClinicalTrials.gov registry entry for NCT00314873 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gleevec (imatinib) is the first listed.
NCT00314873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00314873 about?
NCT00314873 is a clinical study titled "Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma". This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit and/or PDGF. If this current trial is positive, it opens the door to evaluate other combination of drugs with imatinib in thymic tumors.
What is the current status of trial NCT00314873?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2006-04. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00314873?
The interventions under investigation include: Gleevec (imatinib) (DRUG).
Who is sponsoring clinical trial NCT00314873?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.